| Last Action | 01/07/20: to Health and Family Services (H) |
|---|---|
| Title | AN ACT relating to controlled substances. |
| Bill Documents | Introduced |
| Bill Request Number | 8 |
| Sponsor | D. Bentley |
| Summary of Original Version | Create a new section of KRS Chapter 218A to require a practitioner to offer a prescription for naloxone hydrochloride or another drug approved by the Food and Drug Administration for the complete or partial reversal of opioid depression when prescribing an opioid drug and to provide education on overdose prevention and on use of an opioid depression reversal drug; amend KRS 218A.172 to delete reference to Schedule III controlled substances containing hydrocodone and to add issues that a practitioner is required to discuss with a patient prior to prescribing or dispensing a controlled substance to a patient; amend KRS 205.529, 218A.205, and 304.17A-165 to delete reference to Schedule III controlled substances containing hydrocodone. |
| Index Headings of Original Version |
Drugs and Medicines - Controlled substances, risks, benefits, limitations, practitioner discussion with patient Drugs and Medicines - Opioid depression reversal drug, requiring prescription of Health and Medical Services - Controlled substances, risks, benefits, limitations, practitioner discussion with patient Nurses - Controlled substances, risks, benefits, limitations, discussion with patient Nurses - Opioid depression reversal drug, requiring prescription of Pharmacists - Controlled substances, risks, benefits, limitations, discussion with patient Physicians and Practitioners - Controlled substances, risks, benefits, limitations, discussion with patient Physicians and Practitioners - Opioid depression reversal drug, requiring prescription of |
| 10/24/19 |
|
|---|---|
| 01/07/20 |
|
Last updated: 10/27/2020 12:10 PM (EDT)
To receive notice when the record is updated follow @LRCTweetBot. @LRCTweetBot